ALNY vs. BMRN, RPRX, UTHR, IONS, MDGL, GMAB, TEVA, VTRS, BGNE, and KRTX
Should you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include BioMarin Pharmaceutical (BMRN), Royalty Pharma (RPRX), United Therapeutics (UTHR), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Genmab A/S (GMAB), Teva Pharmaceutical Industries (TEVA), Viatris (VTRS), BeiGene (BGNE), and Karuna Therapeutics (KRTX). These companies are all part of the "pharmaceutical preparations" industry.
Alnylam Pharmaceuticals (NASDAQ:ALNY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.
BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
BioMarin Pharmaceutical received 445 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.10% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.83% of users gave BioMarin Pharmaceutical an outperform vote.
Alnylam Pharmaceuticals presently has a consensus price target of $216.12, indicating a potential upside of 48.24%. BioMarin Pharmaceutical has a consensus price target of $107.61, indicating a potential upside of 20.25%. Given Alnylam Pharmaceuticals' higher probable upside, equities research analysts clearly believe Alnylam Pharmaceuticals is more favorable than BioMarin Pharmaceutical.
Alnylam Pharmaceuticals has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.
93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
BioMarin Pharmaceutical has a net margin of 6.93% compared to Alnylam Pharmaceuticals' net margin of -24.08%. BioMarin Pharmaceutical's return on equity of 5.01% beat Alnylam Pharmaceuticals' return on equity.
In the previous week, BioMarin Pharmaceutical had 6 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 15 mentions for BioMarin Pharmaceutical and 9 mentions for Alnylam Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 0.37 beat Alnylam Pharmaceuticals' score of 0.12 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.
Summary
BioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 14 of the 18 factors compared between the two stocks.
Get Alnylam Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alnylam Pharmaceuticals Competitors List
Related Companies and Tools
